Add to watchlist:

Only registered members can add into watchlist !

Register here !
Deal ANGLE plc Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

ANGLE plc is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health.


ANGLE plc’s lead product is the Parsortix cell separation system, which can capture very rare cells from blood. This includes circulating tumor cells (CTCs) in cancer patient blood – even when...

Read more

ANGLE's Parsortix breakthough is 'major step forward', says chief executive

Having proved its ability to capture and count very rare circulating tumour cells (CTCs) in the blood, ANGLE has developed a process for recovering captured cells from the Parsortix cassette

Today's news from ANGLE (LON:AGL) is a "major step forward" chief executive and founder of the firm Andrew Newland told Proactive.

Shares soared 100% after the medical technology group announced a “major breakthrough” in finding a new use for its Parsortix cancer diagnostic device.

Having proved its ability to capture and count very rare circulating tumour cells (CTCs) in the blood, ANGLE has developed a process for recovering captured cells from the Parsortix cassette.

The ability to recover cells in this way allows them to be analysed and also “substantially extends” the technology’s use, opening up “many new diagnostic, prognostic and treatment applications for cancer patients”.

In doing so it “greatly increases” the size of the market available to ANGLE.

Andrew Newland, the company’s founder and chief executive, said: "This major development means that our system now offers two approaches to analysis of CTCs: counting and identification of cells captured within the cassette; and molecular analysis of cells recovered from the cassette as a liquid biopsy.

“We know from discussions with researchers and physicians that there is market demand for this versatility."

Later he told Proactive Investors: "It's moved our technology forward massively so I'm quite pleased the market has recognised that."

In terms of potential, he added: "It greatly increases the size of the market because effectively it leapfrogs all the other technologies out there and enables the clinicians to actually start to work out exactly what type of mutation of cancer the patient has and exactly which of a variety of drugs for example would be most appropriate for that patient."

He said ANGLE had already assessed the existing clinical market for the counting tool alone as £6bn per year.

"This (capture facility) will potentially double that but we haven't got a detailed market analysis because it's all so new," he added.

Looking ahead, ANGLE said it anticipated the Paterson Institute, a world leader working on mutations of circulating tumour cells, would in due course be investigating medical applications of the product using this capture system.

He added that within the next month or so, the company planned to start selling the product to research units, initially in the UK, then in the US.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.